EODData

MEMBERSHIP REGISTER LOG IN

FRA, I7G0: IPSEN SA SP.ADR 1/4/ EO 1

10 Jul 2026
LAST:

41.40

CHANGE:
 0.40		OPEN:
42.00		HIGH:
42.00		ASK:
0.00		VOLUME:
0
CHG(%):
0.96		PREV:
41.80		LOW:
41.40		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
10 Jul 2642.0042.0041.4041.400
09 Jul 2641.8041.8041.8041.800
08 Jul 2641.8041.8041.8041.800
07 Jul 2642.2042.2042.2042.200
06 Jul 2643.0043.0043.0043.000
03 Jul 2642.6042.6042.6042.600
02 Jul 2641.2041.2041.2041.200
30 Jun 2641.4041.4041.4041.400
29 Jun 2640.4040.4040.4040.400
25 Jun 2640.6040.6040.6040.600

PROFILE

Name:IPSEN SA SP.ADR 1/4/ EO 1
About:Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Sector:Healthcare
Address:65, quai Georges Gorse, Boulogne-Billancourt, France, 92100
Website:https://www.ipsen.com
ISIN:US4626292050
LEI:549300M6SGDPB4Z94P11

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:22.54 
Forward P/E:10.63 
Price to Sales:2.66 
Price to Book:0.59 
Profit Margin:0.12 
Operating Margin:0.26 
Return on Assets:0.10 
Return on Equity:0.11 
DivYield:0.05 
Div/Share:1.40 
Revenue:3.76B 
EBITDA:1.377B 
Shares:330.76M 
Market Cap:13.694B 

TECHNICAL INDICATORS

MA5:42.041.5%
MA10:41.640.6%
MA20:40.372.6%
MA50:40.183.0%
MA100:39.764.1%
MA200:35.3017.3%
STO9:38.46
STO14:65.22
RSI14:60.47 
WPR14:-34.78
MTM14:3.00
ROC14:0.08 
ATR:0.63 
Week High:43.003.9%
Week Low:41.400.0%
Month High:43.003.9%
Month Low:38.4017.3%
Year High:43.003.9%
Year Low:25.5162.3%
Volatility:23.56 

RECENT DIVIDENDS

Date Amount
09 Jun 2025$0.34
31 May 2024$0.28
02 Jun 2023$0.27
31 May 2022$0.27